2.00	Reolysin	Reolysin	As of 2010 The Company is conducting phase II trials in a range of indications including squamous cell carcinoma of the lung, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. The Company is also conducting a phase I trial in colorectal cancer.	
